OmnimAbs is a biopharmaceutical company specializing in antibody discovery technology, providing a fully human antibody development platform, including genetically modified animals such as OmniRat ®、 OmniMouse ®） And in vitro screening techniques such as OmniSeq ®）。 Its technology can efficiently generate diverse antibody candidate drugs and has helped partners promote over 45 clinical stage projects. The company collaborates with global pharmaceutical companies through an authorized partnership model to develop innovative therapies in fields such as oncology and autoimmune diseases.

Hand in hand, lead the way of life and health with science. We have a wide range of scientific research product portfolios, advanced drug development and manufacturing capabilities, and a fully integrated service platform that provides CDMO and contract testing services for traditional and new pharmaceuticals. We are committed to benefiting the world with innovative products, high-quality services, and digital solutions, and creating a sustainable future for the next generation.